The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) was established in 1993. Inaugurated in Lisbon in 1995, it is one of the EU’s decentralised agencies. The EMCDDA exists to provide the EU and its Member States with a factual overview of European drug problems and a solid evidence base to support the drugs debate. Today it offers policymakers the data they need for drawing up informed drug laws and strategies. It also helps professionals and practitioners working in the field pinpoint best practice and new areas of research.
The EMCDDA was set up to provide 'factual, objective, reliable and comparable information concerning drugs, drug addiction and their consequences'
Objective: to discuss the results of the report Prison and drugs in Europe: current and future challenges Insights with key customers.
Invited Stakeholders:
Objective: A conversation with former European Drugs School students on their careers and the legacy of the school.
Introduction: Marica Ferri (EMCDDA) and Isabel Flores (ISCTE-IPPS)
Chair: Alessandra Bo
Guests:
How has the COVID-19 pandemic affected drug use and supply? What drugs are causing the most concern today? What are the latest trends in drug production and trafficking? Find out more when the EU drugs agency (EMCDDA) launches its European Drug Report 2021: Trends and Developments in a live online media event on 9 June.
